Dendritic cells (DCs), as the professional antigen presenting cells (APCs), are critical determinants of initiating and sustaining effective T-cell-mediated anti-tumor immune responses. As tumor-induced immunosuppression remains one of the major hurdles for cancer immunotherapy, understanding how DCs administer T cell anti-cancer immunity in tumor microenvironment (TME) should be intensively elucidated. DCs lead anti-cancer immune response by uptaking, processing, and presenting tumor antigens to activate antigen-specific T cells.
Although DC vaccines are armed with tumor associated antigens (TAA), adjuvants still need to be considered to in DC vaccine strategies to yield maximum clinical success. TAA and/or adjuvants can be encapsulated in delivery systems such as peptide/mRNA conjugates (for example, polysaccharides, C type lectin receptors or nanoparticles), self-polymerizing scaffolds or oncolytic viruses. Choosing a suitable adjuvant is important as it can potentially override tumor immunosuppressive microenvironment and allow DCs-T cell immune responses to maximize its therapeutic potential.
Overall, we need to learn more about how we can optimally exploit specific DCs to orchestrate efficacious immune responses against cancer.
The goal of this Research Topic is to provide a forum to advance research and clinical translation on the contribution of dendritic cells-based anti-tumor immune responses. The rapidly expanding clinical use of immunotherapy provides urgency to dissect the mechanisms underlying therapeutic responses and resistance, and to understand how DC immunobiology can be leveraged to improve response rates and treatment outcomes for patients with cancer.
We welcome submissions of Original Research, Review and Mini Review on the sub-topics below:
• Methods of targeting DCs/APCs
• Prophylactic and/or therapeutic strategies for DCs/APCs based vaccines
• Immunologic adjuvant to improve the efficacy of DCs/APCs-based vaccines
• Cancer specific peptide/mRNA delivery systems to DCs/APCs cells
• Human clinical trials using DCs/APCs based vaccines against cancer
• Combination studies – e.g. Chemotherapy/radiotherapy/ICB+ DCs/APCs based vaccines
Dendritic cells (DCs), as the professional antigen presenting cells (APCs), are critical determinants of initiating and sustaining effective T-cell-mediated anti-tumor immune responses. As tumor-induced immunosuppression remains one of the major hurdles for cancer immunotherapy, understanding how DCs administer T cell anti-cancer immunity in tumor microenvironment (TME) should be intensively elucidated. DCs lead anti-cancer immune response by uptaking, processing, and presenting tumor antigens to activate antigen-specific T cells.
Although DC vaccines are armed with tumor associated antigens (TAA), adjuvants still need to be considered to in DC vaccine strategies to yield maximum clinical success. TAA and/or adjuvants can be encapsulated in delivery systems such as peptide/mRNA conjugates (for example, polysaccharides, C type lectin receptors or nanoparticles), self-polymerizing scaffolds or oncolytic viruses. Choosing a suitable adjuvant is important as it can potentially override tumor immunosuppressive microenvironment and allow DCs-T cell immune responses to maximize its therapeutic potential.
Overall, we need to learn more about how we can optimally exploit specific DCs to orchestrate efficacious immune responses against cancer.
The goal of this Research Topic is to provide a forum to advance research and clinical translation on the contribution of dendritic cells-based anti-tumor immune responses. The rapidly expanding clinical use of immunotherapy provides urgency to dissect the mechanisms underlying therapeutic responses and resistance, and to understand how DC immunobiology can be leveraged to improve response rates and treatment outcomes for patients with cancer.
We welcome submissions of Original Research, Review and Mini Review on the sub-topics below:
• Methods of targeting DCs/APCs
• Prophylactic and/or therapeutic strategies for DCs/APCs based vaccines
• Immunologic adjuvant to improve the efficacy of DCs/APCs-based vaccines
• Cancer specific peptide/mRNA delivery systems to DCs/APCs cells
• Human clinical trials using DCs/APCs based vaccines against cancer
• Combination studies – e.g. Chemotherapy/radiotherapy/ICB+ DCs/APCs based vaccines
